Department of Respiratory Medicine, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi, 417000, People's Republic of China.
Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Sciences, Central South University, 172 Tongzipo Road, Changsha, 410013, People's Republic of China.
Stem Cell Res Ther. 2020 Jul 16;11(1):291. doi: 10.1186/s13287-020-01802-8.
Acute respiratory distress syndrome virus-2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) infection, which causes global public health emergencies, has sped widely for more than 5 months and has the risk of long-term transmission. No effective treatment has been discovered to date. In the cases we report, the patient continued to deteriorate even after administration of antiviral drugs such as lopinavir/ritonavir, interferon-α, and ribavirin, as well as intravenous injection of meropenem, methylprednisolone, and immunoglobulin. So, we infused the patient with convalescent plasma (CP), and the absolute lymphocyte count increased the next day and returned to normal on the fourth day. Followed by intravenous infusion of mesenchymal stem cells (MSCs), bilateral infiltrates were absorbed and the pulmonary function was significantly improved. We note that the intravenous infusion of CP and MSCs for the treatment of severe COVID-19 patients may have synergistic characteristics in inhibiting cytokine storm, promoting the repair of lung injury, and recovering pulmonary function. We hope to provide a reference for the research direction of COVID-19 clinical strategies.
急性呼吸窘迫综合征病毒-2（SARS-CoV-2）可引起 2019 年冠状病毒病（COVID-19）感染，导致全球突发公共卫生事件，其传播速度已超过 5 个月，并存在长期传播的风险。迄今为止，尚未发现有效的治疗方法。在我们报告的病例中，即使给予洛匹那韦/利托那韦、干扰素-α和利巴韦林等抗病毒药物，以及美罗培南、甲基强的松龙和免疫球蛋白静脉注射，患者仍持续恶化。因此，我们给患者输注了恢复期血浆（CP），第二天绝对淋巴细胞计数增加，第四天恢复正常。随后静脉输注间充质干细胞（MSCs），双肺浸润吸收，肺功能明显改善。我们注意到，CP 和 MSCs 的静脉输注治疗严重 COVID-19 患者可能在抑制细胞因子风暴、促进肺损伤修复和恢复肺功能方面具有协同作用。我们希望为 COVID-19 临床策略的研究方向提供参考。
